Cantor Fitzgerald Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its price target boosted by stock analysts at Cantor Fitzgerald from $135.00 to $155.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 2.10% from the stock’s previous close.

Several other analysts have also issued reports on GILD. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. Daiwa Securities Group upped their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Truist Financial increased their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Finally, TD Cowen lifted their target price on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $152.42.

Gilead Sciences Trading Down 2.6%

GILD opened at $151.81 on Wednesday. The stock has a market capitalization of $188.35 billion, a PE ratio of 22.42, a P/E/G ratio of 0.81 and a beta of 0.36. Gilead Sciences has a one year low of $93.37 and a one year high of $157.29. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. The business’s 50 day moving average price is $129.59 and its 200 day moving average price is $121.98.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the business earned $1.90 earnings per share. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the sale, the chief executive officer directly owned 613,912 shares in the company, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of large investors have recently made changes to their positions in GILD. Csenge Advisory Group lifted its stake in Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd increased its holdings in shares of Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the period. TriaGen Wealth Management LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at about $1,274,000. iA Global Asset Management Inc. lifted its position in shares of Gilead Sciences by 11.6% in the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after purchasing an additional 23,046 shares in the last quarter. Finally, Sector Gamma AS boosted its holdings in shares of Gilead Sciences by 15.9% during the third quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after purchasing an additional 20,239 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.